Drug Approval | December 11, 2025
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The study met its primary endpoint and all 11 secondary efficacy endpoints
HYMPAVZI’s safety profile was generally favorable
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Subscribe To Our Newsletter & Stay Updated
